Expression of Polycomb Targets Predicts Breast Cancer Prognosis

Global changes in the epigenome are increasingly being appreciated as key events in cancer progression. The pathogenic role of enhancer of zeste homolog 2 (EZH2) has been connected to its histone 3 lysine 27 (H3K27) methyltransferase activity and gene repression; however, little is known about relationship of changes in expression of EZH2 target genes to cancer characteristics and patient prognosis. Here we show that through expression analysis of genomic regions with H3K27 trimethylation (H3K27me3) and EZH2 binding, breast cancer patients can be stratified into good and poor prognostic groups independent of known cancer gene signatures. The EZH2-bound regions were downregulated in tumors characterized by aggressive behavior, high expression of cell cycle genes, and low expression of developmental and cell adhesion genes. Depletion of EZH2 in breast cancer cells significantly increased expression of the top altered genes, decreased proliferation, and improved cell adhesion, indi-cating a critical role played by EZH2 in determining the cancer phenotype. Recognition of the role of the epigenome during the formationof cancer genomes may help to explain aspects of tumor de-velopment such as the late onset of most solid tumors, recurrent disease, tumor heterogeneity, risk factors, and environmental ef-fects (1, 2). Deregulation of Polycomb repressive complex 2 (PRC2) proteins EZH2 and SUZ12 has been linked to the initia-tion of tumorigenesis through a variety of mechanisms, whic